The latest from BioStock
» Alligator's CEO: "We are not surprised by the positive readout"
» NanoEcho's nanoparticle reaches goal in phase III study
» Australian no to lecanemab
» BioInvent prepares for a data-rich 2025
» Elicera CEO: "TO2 a very attractive opportunity to increase ownership in Elicera"
Read the newsletter for v.9 here.
The latest news
and Saniona announces initial positive results from the Phase I study with ACP-711 (formerly SAN711). Read more.
BioArctic informs that the Australian Medicines Agency has decided not to approve lecanemab. Read more.
Faron Pharmaceuticals announces that the FDA grants orphan drug designation for bexmarilimab in MDS. Read more.
Iconovo receives a grant of SEK 670 from Innowwide for investment in the Japanese market. Read more.
Odinwell announces that it has been granted business support (R&D check) from Region Halland of just over SEK 160. Read more.
Subscription price determined for the exercise of warrants of series TO3 in Scandinavian Real Heart. Read more.
Camurus announces that Jon Garay Alonso will leave his position as the company's Chief Financial Officer for personal reasons. Read more.
NanoEchos Selected iron oxide-based nanoparticles achieve primary goals in a phase III MRI study. Read more.
SynAct Pharma is granted a central patent in the US for Resomelagon (AP1189). Read more.
Spago Nanomedical is proceeding with increased dose in the phase I/IIa study Tumorad-01. Read more.
AcouBlack and Bio-ReCell has signed a letter of intent to explore the development of a system for automated purification and isolation of stem cells and immune cells from adipose tissue. Read more.
Diagonal Cinema applies for a change of marketplace to NGM Nordic SME. Read more.
sectra receives new orders from Swedish authorities. Read more.
Inhalation Sciences comments on the FDA's latest guidelines regarding inhalation products. Read more.
Today the subscription period begins in Gabathers rights issue and the company invites to web conferences. Read more.
Magnasense Technologies and Salofa reaches an agreement. Read more.
Orioles The board of directors recommends that the shareholders' proposal regarding a combination of share classes and a directed issue of shares without payment be adopted at the annual general meeting.. Read more.
Zelluna, previously Ultimovacs, is listed on the Oslo Stock Exchange following the successful completion of a corporate acquisition and private placement. Read more.
Last day of trading in Abliva will be March 17, 2025. Read more.
Hansa Biopharma participates in the Leerink Partners Global Healthcare Conference. Read more.
Reports
Insider trading and transactions
AstraZeneca Embla Gentian Diagnostics Gentian Diagnostics (2) Nexstim Oculis Holding Orion PolarCool Promimic
